AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 82 min read$TLRY

Tilray reports mixed Q1 results; reaffirms FY27 outlook

Tilray reported Q1 results with Non-GAAP EPS of $0.02, beating estimates by $0.16. Revenue was $257.15M, up 22.7% year-over-year but missed expectations by $9.65M. The company's international business grew, particularly in EMEA, with a 71% increase in revenue. Tilray reaffirmed its FY27 outlook.

Original reporting
seekingalpha.com
Published Oct 8, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TLRY
Neutral
medium confidence
Mentioned
$TLRY
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$TLRYNeutralMed
01

Why it matters

The earnings beat on EPS may provide short‑term support, but the revenue miss could dampen momentum.

02

Market read

First‑report earnings for a mid‑cap cannabis company, offering fresh data for traders.

03

What to watch

Potential cost reductions or upcoming product launches not reflected in the current quarter.

Relevance 7/10Novelty 8/10Timing: today

Background

Tilray Brands, Inc. released its Q1 2026 earnings, reporting mixed results.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

Q1 2026 earnings report showing Non-GAAP EPS of $0.02 beating expectations and revenue of $257.15M missing estimates.

Expected impact

modest downside as revenue shortfall may pressure the stock despite EPS beat

Evidence & confidence

Revenue miss suggests slower growth, offset by a small EPS beat, likely leading to limited price movement.

Market effects

Sector

Cannabis sector may see modest valuation adjustments as Tilray's revenue miss highlights demand concerns.

Regional

North American cannabis stocks could experience slight pressure.

Global

Limited, primarily affecting investors focused on the cannabis industry.

Counterpoint

What could challenge this read

Investors might view the EPS beat as a sign of operational efficiency and could buy on dip.

Key entities

  • company
    Tilray Brands, Inc.

    US‑listed cannabis producer (ticker TLRY).

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min